DCGI permits Panacea Biotec's Baddi unit to manufacture Sputnik V vaccine

Panacea Biotec announced that it had received a license from the Drugs Controller General of India (DCGI) to manufacture Sputnik V vaccine against COVID-19 at its Baddi facility in Himachal Pradesh.

"The said batches have successfully passed all the checks for quality parameters both at the Gamaleya Center in Russia and at the Central Drug Laboratory, Kasauli, Himachal Pradesh in India," Panacea told stock exchanges on July 5.

Panacea is manufacturing Sputnik V in a collaboration with Russia's sovereign wealth fund Russian Direct Investment Fund (RDIF). RDIF has signed fixed price manufacturing contracts with half a dozen India companies including Panacea. Except for Panacea, others were manufacturing the vaccine for the first time. Dr Reddy's will be distributing the first 250 million doses that inoculate (125 million people).

"Panacea Biotec is delighted to announce the obtaining of the manufacturing license to produceSputnik V vaccine in India. At this occasion, we thank the leadership of our Hon'ble Prime MinisterModi ji and Government of India for timely handholding and expediting clearances to enable 'Makein India' vaccines," said Dr. Rajesh Jain, Managing Director of Panacea Biotec.